C-Reactive Protein as a Possible Predictor of Trail-Making Performance in Individuals with Psychiatric Disorders.


Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
02 Oct 2020
Historique:
received: 07 09 2020
revised: 23 09 2020
accepted: 29 09 2020
entrez: 7 10 2020
pubmed: 8 10 2020
medline: 31 3 2021
Statut: epublish

Résumé

Cognitive dysfunction is a prominent feature of psychiatric disorders. Studies have shown that systemic low-grade inflammation is crucial in the development of cognitive deficits across psychiatric disorders. The aim of this study was to further examine the role of inflammation and inflammatory mediators in cognitive function in psychiatric disorders. This study included 364 inpatients (53% females) with International Classification of Diseases (ICD)-10 F3 (affective disorders) and F4 (neurotic, stress-related, and somatoform disorders) diagnoses. The mean age was 52 years (22 to 69 years) and the median body mass index was 27.6. Cognitive function was assessed with the Color-Word Interference Test after Stroop and the Trail-Making Test A/B. Multiple linear regression models were calculated to assess the predictive value of C-reactive protein and the kynurenine/tryptophan ratio on cognitive function controlling for age, sex, education, premorbid verbal intelligence quotient illness duration, depressive symptoms, and obesity-related parameters (e.g., body mass index, high-density lipoprotein). Our data confirm that in patients with psychiatric disorders, C-reactive protein serum concentration is a relevant and important predictor of Trail-Making Test B performance, measuring cognitive flexibility. The effect size of this association did not change much after adding clinical and metabolic variables into the regression model. The kynurenine/tryptophan ratio was not related to cognitive test scores. The involvement of C-reactive protein as a peripheral inflammatory marker in cognitive flexibility and psychomotor processing speed in psychiatric illness can be concluded.

Identifiants

pubmed: 33023087
pii: nu12103019
doi: 10.3390/nu12103019
pmc: PMC7599970
pii:
doi:

Substances chimiques

Biomarkers 0
Inflammation Mediators 0
Kynurenine 343-65-7
Tryptophan 8DUH1N11BX
C-Reactive Protein 9007-41-4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Psychiatry Res. 2006 Nov 29;145(1):39-48
pubmed: 17045658
JAMA. 2004 Nov 10;292(18):2237-42
pubmed: 15536110
Psychoneuroendocrinology. 2015 Jan;51:219-26
pubmed: 25462895
Schizophr Res. 2018 Feb;192:16-29
pubmed: 28416092
J Affect Disord. 2009 Dec;119(1-3):1-8
pubmed: 19428120
Curr Med Chem. 2014 Jun;21(17):1931-7
pubmed: 24606499
FEBS J. 2009 Oct;276(20):5747-54
pubmed: 19754872
PLoS One. 2017 Feb 27;12(2):e0172699
pubmed: 28241062
Psychol Med. 2014 Jul;44(10):2029-40
pubmed: 24168753
Psychol Med. 2009 Mar;39(3):413-23
pubmed: 18533059
Lancet Neurol. 2005 Jun;4(6):371-80
pubmed: 15907742
Neuromolecular Med. 2011 Jun;13(2):93-116
pubmed: 21165712
Acta Neurol Scand. 1995 May;91(5):335-45
pubmed: 7639062
Arch Gen Psychiatry. 2001 Mar;58(3):221-7
pubmed: 11231827
Clin Chem. 1997 Dec;43(12):2424-6
pubmed: 9439467
J Psychiatr Res. 2013 Sep;47(9):1119-33
pubmed: 23768870
Brain Behav Immun. 2011 Aug;25(6):1272-8
pubmed: 21605657
J Neuroinflammation. 2014 Sep 02;11:151
pubmed: 25178630
J Affect Disord. 2012 Oct;140(2):113-24
pubmed: 22088608
Biol Psychiatry. 2011 Jul 15;70(2):175-82
pubmed: 21277567
Psychosom Med. 2009 Feb;71(2):171-86
pubmed: 19188531
Mol Cell Endocrinol. 2010 Mar 25;316(2):104-8
pubmed: 19628019
J Affect Disord. 2013 Sep 25;150(3):736-44
pubmed: 23870425
Neurobiol Aging. 2016 Feb;38:112-117
pubmed: 26827649
J Affect Disord. 2014 Aug;164:130-8
pubmed: 24856566
Mol Psychiatry. 2016 Dec;21(12):1696-1709
pubmed: 26903267
Psychoneuroendocrinology. 2018 Apr;90:61-67
pubmed: 29433074
Brain Behav Immun. 2012 Jan;26(1):90-5
pubmed: 21839826
Psychiatry Clin Neurosci. 2007 Dec;61(6):616-21
pubmed: 18081621
Psychol Med. 2008 Jun;38(6):771-85
pubmed: 17922938
Schizophr Res. 2014 Jul;156(2-3):248-53
pubmed: 24827555
J Psychosom Res. 2017 May;96:49-59
pubmed: 28545793
Obes Rev. 2011 Nov;12(11):968-83
pubmed: 21762426
Nat Rev Drug Discov. 2012 Feb 01;11(2):141-68
pubmed: 22293568
J Am Geriatr Soc. 2007 May;55(5):708-16
pubmed: 17493190
Inflammation. 2008 Jun;31(3):198-207
pubmed: 18347963
Psychoneuroendocrinology. 2014 Jul;45:202-10
pubmed: 24845191
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
J Neurochem. 2011 Oct;119(1):136-52
pubmed: 21819405
Int J Obes (Lond). 2005 Dec;29(12):1452-6
pubmed: 16077717
Obes Rev. 2013 Mar;14(3):232-44
pubmed: 23171381
Neuropsychol Rev. 2006 Mar;16(1):17-42
pubmed: 16794878
Biol Psychiatry. 2010 Mar 1;67(5):446-57
pubmed: 20015486
Child Neuropsychol. 2010;16(3):279-92
pubmed: 20234954
PLoS One. 2012;7(8):e43382
pubmed: 22927962
Psychoneuroendocrinology. 2017 Jul;81:144-150
pubmed: 28482311
Complement Ther Med. 2015 Feb;23(1):32-7
pubmed: 25637150
J Clin Exp Neuropsychol. 2004 May;26(3):441-50
pubmed: 15512932
Int J Obes (Lond). 2011 Nov;35(11):1363-76
pubmed: 21343903
Bipolar Disord. 2014 Jun;16(4):432-40
pubmed: 24330408
Psychol Health. 2008;23(3):309-26
pubmed: 25160480
J Affect Disord. 2006 Jul;93(1-3):105-15
pubmed: 16677713
Appl Neuropsychol. 2002;9(2):106-9
pubmed: 12214820
Arch Neurol. 2004 May;61(5):668-72
pubmed: 15148142
Obesity (Silver Spring). 2009 Oct;17(10):1957-63
pubmed: 19478788
J Neuroimmunol. 2003 Jan;134(1-2):142-50
pubmed: 12507782
CNS Spectr. 2019 Feb;24(1):4-15
pubmed: 30714555
Brain Behav Immun. 2014 Jan;35:70-6
pubmed: 24016864
Psychol Med. 2013 Jun;43(6):1161-73
pubmed: 23237010
Nat Rev Neurosci. 2008 Jul;9(7):568-78
pubmed: 18568016
Psychol Bull. 2013 Jan;139(1):81-132
pubmed: 22642228
J Clin Invest. 2004 Dec;114(12):1752-61
pubmed: 15599400

Auteurs

Nina Dalkner (N)

Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, 8036 Graz, Austria.

Eva Reininghaus (E)

Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, 8036 Graz, Austria.

Karin Schwalsberger (K)

Therapiezentrum Justuspark, 4540 Bad Hall, Austria.

Alexandra Rieger (A)

Therapiezentrum Justuspark, 4540 Bad Hall, Austria.

Carlo Hamm (C)

Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, 8036 Graz, Austria.
Therapiezentrum Justuspark, 4540 Bad Hall, Austria.

René Pilz (R)

Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, 8036 Graz, Austria.

Melanie Lenger (M)

Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, 8036 Graz, Austria.

Robert Queissner (R)

Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, 8036 Graz, Austria.

Valerie S Falzberger (VS)

Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, 8036 Graz, Austria.

Martina Platzer (M)

Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, 8036 Graz, Austria.

Frederike T Fellendorf (FT)

Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, 8036 Graz, Austria.

Armin Birner (A)

Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, 8036 Graz, Austria.

Susanne A Bengesser (SA)

Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, 8036 Graz, Austria.

Elisabeth M Weiss (EM)

Institute of Psychology, University of Innsbruck, 6020 Innsbruck, Austria.

Roger S McIntyre (RS)

Department of Psychiatry and Pharmacology, University of Toronto, Toronto, ON 399, Canada.

Harald Mangge (H)

Research Unit on Lifestyle and Inflammation-associated Risk Biomarkers, Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University, 8036 Graz, Austria.
BioTechMed-Graz, 8036 Graz, Austria.

Bernd Reininghaus (B)

Therapiezentrum Justuspark, 4540 Bad Hall, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH